Navigation Links
Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
Date:12/10/2009

TARRYTOWN, N.Y., Dec. 10 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast its presentation at the Deutsche Bank 2009 Biotech Boston Confab on Tuesday, December 15, 2009. The presentation is scheduled for 3:35 p.m. Eastern Time. The session may be accessed through the Company's web site, www.regeneron.com, on the Investor Relations page. An archived version of the presentation will be available after the live webcast through January 15, 2010. Additional information about Regeneron and recent news releases are available on the Regeneron web site.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has preclinical programs in other diseases and disorders.


Contact Information:

Peter Dworkin                  Laura Lindsay
Investor Relations             Media Relations
914.345.7640                   914.345.7800
peter.dworkin@regeneron.com    laura.lindsay@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.


'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Summary This report provides all the ... partnering interests and activities since 2010. Description The Partnering ... into the partnering activity of one of the world,s leading ... prepared upon purchase to ensure inclusion of the most up ... will be delivered in PDF format within 1 working day ...
(Date:3/27/2017)... 27, 2017  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" ... offer shares of common stock in an underwritten public ... with the Securities and Exchange Commission (the "SEC"). The ... there can be no assurance as to whether or ... the actual size or terms of the offering. Cryoport ...
(Date:3/27/2017)... Calif. , March 27, 2017  Sanderling ... acquired by Ethicon, a division of Johnson & ... System for the treatment of gastro-esophageal reflux disease ... sphincter augmentation (MSA) technology and the procedure is ... centers. Torax Medical was founded by ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... The Radiology Business ... has begun to serve as its new executive director. Mr. Still was selected through ... Committee. , “Bob, as he is known to our members, has been a ...
(Date:3/28/2017)... , ... March 28, 2017 , ... With less than ... acne, access to quality care can be limited while the desire to conquer breakouts ... customized prescription acne care for every customer online, today released its inaugural survey on ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... patients desire to achieve the “perfect smile.” The National Association of Dental Laboratories ... as what dentists should be aware of when utilizing dental laboratories and technicians ...
(Date:3/28/2017)... ... March 28, 2017 , ... With expansion and efficiency in mind, Patten Seed ... The seed processing plant opened in Marshallville in 2006, and a bagging and shipping ... opportunity for transition of Patten Seed operations to the Middle Georgia location from their ...
(Date:3/28/2017)... ... ... that reveals the mystery of Kevin’s purpose. “A Prophets Bones” is the creation of published ... him that he had neglected to do, but this was from God and there was ... would have felt themselves to be special and better than others due to the fact ...
Breaking Medicine News(10 mins):